Drugmaker Cipla Ltd . delivered US sales worth $233 million during the September quarter on Thursday, October 30, which was higher than most analyst projections and flat on a year-on-year basis. When compared sequentially, the figure was marginally higher. The stock, in response, has recovered from the lows of the day.

Motilal Oswal had projected Cipla's US sales to fall 12% from last year to $220 million, while Kotak estimated sales to decline 3% sequentially to $220 million. For the June quarter, Cipla had reported US sales of $226 million.

By calendar year 2026, Cipla expects to launch four major respiratory assets, including the generic Advair in the fourth quarter of financial year 2026, and three peptide assets, including Liraglutide. Three out of the four respiratory assets are

See Full Page